ClinicalTrials.gg
CompletedNCT00647491Updated Mar 31, 2008

A Study of Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis

A Phase 2/3 interventional study of adalimumab and adalimumab in Rheumatoid Arthritis, sponsored by Abbott. Completed at 25 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2008-03-31.

Sponsored by Abbott · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
352
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 87 studies testing adalimumab in Arthritis, Rheumatoid — 4 open to participants now, 6 under way, 2 of them phase 3. Adalimumab · Arthritis, Rheumatoid.

Enrollment
27th of 87
352 · median 160
Started
2004
with 4 others
Phase 2/3
3 of 87
none open now
Registered
22nd of 87
by date
Lead sponsor
22 of 87
Abbott

Among the 87 studies testing adalimumab in Arthritis, Rheumatoid, this one is the 27th largest by enrollment, is one of 5 that started in 2004, is one of 3 in phase 2/3, and was the 22nd registered.

Arthritis, Rheumatoid

3,336 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

4 of the 87 studies testing adalimumab in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About adalimumab

Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 87 studies testing adalimumab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the safety, efficacy and pharmacokinetics of three doses of adalimumab in adult Japanese subjects with RA

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Meet ACR criteria for diagnosis of active RA and have at both screening and baseline visits >10 swollen joints, >12 tender joints.
  • Subjects must have failed prior treatment with one or more DMARDs.
  • A negative (serum) pregnancy test for all female subjects of at screening and a negative (urine) pregnancy test prior to study drug administration.
  • Body weight less than or equal to 100 kg

Exclusion criteria

Exclusion Criteria:

  • A history of, or current, acute inflammatory joint disease of different origin from RA.
  • Prior treatment with any TNF antagonist, including adalimumab.
  • Any ongoing chronic or active infection or any major episode of infection requiring hospitalization or treatment with IV antibiotics.
  • Unstable ischemic heart disease, active inflammatory bowel disease, active peptic ulcer disease, recent stroke or any poorly controlled medical condition.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
352 participants (actual)

Study arms

  • Experimental
    20 mg

    20 mg adalimumab eow

    Biological: adalimumab

  • Experimental
    40 mg

    40 mg adalimumab eow

    Biological: adalimumab

  • Experimental
    80 mg

    80 mg adalimumab eow

    Biological: adalimumab

  • Placebo comparator
    Placebo

    Placebo eow

    Biological: placebo

Interventions

  • Biologicaladalimumab

    20 mg sc eow

    Also known as: ABT-D2E7, Humira

  • Biologicaladalimumab

    40 mg sc eow

    Also known as: ABT-D2E7, Humira

  • Biologicaladalimumab

    80 mg sc eow

    Also known as: ABT-D2E7, Humira

  • Biologicalplacebo

    placebo sc eow

06

What researchers measure

Primary outcomes

  1. ACR20

    Time frame: Week 24

Secondary outcomes

  1. ACR20

    Time frame: Week12

  2. ACR50

    Time frame: Weeks 12 and 24

  3. ACR70

    Time frame: Weeks 12 and 24

07

Study locations

25 sites
  • Aichi, Japan
  • Chiba, Japan
  • Ehime, Japan
  • Fukui, Japan
  • Fukuoka, Japan
  • Gunma, Japan
  • Hokkaido, Japan
  • Hyogo, Japan
  • Ibaraki, Japan
  • Ishikawa, Japan
  • Kagoshima, Japan
  • Kanagawa, Japan
  • Kyoto, Japan
  • Miyagi, Japan
  • Nagano, Japan
  • Nagasaki, Japan
  • Niigata, Japan
  • Okayama, Japan
  • Osaka, Japan
  • Saitama, Japan
  • Shizuoka, Japan
  • Tochigi, Japan
  • Tokushima, Japan
  • Tokyo, Japan
  • Toyama, Japan
08

References and documents

Publications

  • Burmester GR, Landewe R, Genovese MC, Friedman AW, Pfeifer ND, Varothai NA, Lacerda AP. Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis. Ann Rheum Dis. 2017 Feb;76(2):414-417. doi: 10.1136/annrheumdis-2016-209322. Epub 2016 Jun 23. PubMed 27338778 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2004, a primary completion of Jun 2005 and a completion of Aug 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2008
First posted
Mar 31, 2008
Start
Feb 2004
Primary completionActual
Jun 2005
CompletionActual
Aug 2005
Last update
Mar 31, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 31, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00647491
Lead sponsor
Abbott
Collaborators
Eisai Limited
First posted
Mar 31, 2008
Start date
Feb 2004
Primary completion
Jun 2005
Completion
Aug 2005
Last update
Mar 31, 2008

Study contacts

Shigeki Hashimoto, Ph.D.
study director · Abbott

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion